本文關鍵詞： 調節(jié)性T細胞 慢性淋巴細胞性白血病 Foxp 預后分析　出處：《細胞與分子免疫學雜志》2013年12期 　論文類型：期刊論文

【摘要】：目的探討慢性淋巴細胞性白血病(CLL)患者外周血中調節(jié)性T細胞(Treg)表達及其與預后的相關性。方法采用流式細胞術檢測30例健康體檢者和28例初診的CLL患者治療前后外周血的CD4+CD25+Treg、CD4+CD25+Foxp3+Treg數量,并對19例患者進行了治療隨訪。結果初診CLL患者CD4+CD25+Treg高于健康對照組,差異有統計學意義(P0.05);初診CLL患者CD4+CD25+Foxp3+Treg分別高于治療后組和健康對照組,差異均有統計學意義(P0.05),治療后CD4+CD25+Foxp3+Treg高于健康對照組,差異有統計學意義(P0.05)。初診CLL患者CD4+CD25+Foxp3+Treg與CD38表達率、β2微球蛋白表達量、Zeta相關蛋白70(ZAP-70)陽性表達、臨床Binet分期和Rai分期均呈正相關。結論 CD4+CD25+Foxp3+Treg有可能作為評估CLL患者疾病進展、療效及預后的指標之一。
[Abstract]:Objective to investigate the expression of regulatory T cell tregs in peripheral blood of patients with chronic lymphoblastic leukemia (CLL) and its correlation with prognosis. Methods flow cytometry was used to detect 30 healthy controls and 28 newly diagnosed CLL patients before treatment. The number of CD4 CD25 Foxp3 Treg in peripheral blood of CD4 CD25 Tregmonium was determined. Results the CD4 CD25 Treg in the newly diagnosed CLL patients was higher than that in the healthy control group (P 0.05), the CD4 CD25 Foxp3 Treg in the newly diagnosed CLL patients was higher than that in the post-treatment group and the healthy control group. After treatment, the CD4 CD25 Foxp3 Treg was significantly higher than that in the healthy control group (P 0.05). The expression rate of CD4 CD25 Foxp3 Treg and CD38 and the expression of 尾 2 microglobulin in the newly diagnosed CLL patients were significantly higher than those in the healthy control group (P 0.05), and the expression of 尾 2 microglobulin and Zeta associated protein 70 (ZAP-70) were positive. Conclusion CD4 CD25 Foxp3 Treg may be one of the indexes to evaluate the disease progression, curative effect and prognosis of CLL patients.
【作者單位】： 新疆醫(yī)科大學第一附屬醫(yī)院血液科;
【基金】：新疆維吾爾自治區(qū)自然科學基金(2013211A100)
【分類號】：R392.11

【相似文獻】

相關期刊論文 前10條

1 于健寧;馬紀林;陶筱娟;王菊華;李向培;鄒和建;鄭頌國;;Foxp3仍然是人調節(jié)性T細胞的標志?[J];中華臨床免疫和變態(tài)反應雜志;2008年01期

2 曹江;陳，

本文編號：1536302